COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00376467
Recruitment Status : Completed
First Posted : September 14, 2006
Last Update Posted : February 7, 2014
Information provided by (Responsible Party):
Gruppo Italiano Malattie EMatologiche dell'Adulto

Brief Summary:

This proposal, developed in the framework of the GIMEMA, will permit:

  • to evaluate the activity and toxicity of imatinib in the treatment of Ph+ acute lymphoblastic leukemia;
  • to evaluate the molecular response to the treatment, and to monitor the molecular status of remission in all cases achieving or not a molecular response.

The GIMEMA has activated a network to centralize all biological samples (bone marrow and peripheral blood) at diagnosis from all new ALL patients. This will permit to identify, in particular, Ph + and/or BCR/ABL + cases within 5 days from diagnosis, thus permitting to treat these patients according to different programs on the basis of the presence of Ph chromosome.

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Drug: Imatinib Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 105 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201.
Study Start Date : December 2001
Actual Primary Completion Date : June 2010
Actual Study Completion Date : February 2011

Primary Outcome Measures :
  1. for Study A, the primary endpoint for activity is overall CMR rate [ Time Frame: after 6 months of imatinib treatment ]
  2. for Study B, the primary endpoint for activity is overall CHR (+/- CMR) rate . [ Time Frame: after induction treatment ]

Secondary Outcome Measures :
  1. complete hematological or molecular remission duration [ Time Frame: at study end ]
  2. overall survival. [ Time Frame: at study end ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Ph +ve and/or BCR/ABL +ve ALL, either in 1st CHR (independently from the molecular status) for study A, or at diagnosis and untreated for study B;
  • Age >18 years and <60 for study A, >60 for study B;
  • Written voluntary informed consent.

Exclusion Criteria:

  • Patients of childbearing potential without a negative pregnancy test prior to the initiation of study. Barrier contraceptive precautions are to be used throughout the trial in both sexes;
  • Pretreatment with steroids for more than 10 days in study B;
  • Serum bilirubin and creatinine values >3 the upper limit of normal range;
  • SGOT and SGPT values >3 the upper limit of the normal range;
  • Patients who had received any other investigational agent within 4 weeks before the enrollment;
  • Patients with cardiovascular diseases grade >3 according to the New York Heart Association (see Appendix 1);
  • Patients with a history of non compliance to medical regimen or who are considered potentially unreliable;
  • Patients with moderate/severe mood or psychiatric disorders;
  • Concomitant neoplasia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00376467

Show Show 28 study locations
Sponsors and Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
Layout table for investigator information
Principal Investigator: Michele Baccarani Università degli Studi di Udine
Publications of Results:
Layout table for additonal information
Responsible Party: Gruppo Italiano Malattie EMatologiche dell'Adulto Identifier: NCT00376467    
Other Study ID Numbers: LAL0201
First Posted: September 14, 2006    Key Record Dates
Last Update Posted: February 7, 2014
Last Verified: February 2014
Keywords provided by Gruppo Italiano Malattie EMatologiche dell'Adulto:
Acute Lymphoblastic Leukemia
Philadelphia positive
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action